Italia markets close in 7 hours 38 minutes

Silence Therapeutics plc (SLN.L)

LSE - LSE Prezzo differito. Valuta in GBp.
Aggiungi a portafoglio
525,00+13,00 (+2,54%)
Al 8:27AM BST. Mercato aperto.

Silence Therapeutics plc

72 Hammersmith Road
London W14 8TH
United Kingdom
44 20 3457 6900
http://www.silence-therapeutics.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno65

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Mark Andrew RotheraPres, CEO & Exec. Director521,23kN/D1963
Dr. Giles V. Campion M.D.Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director436,2kN/D1954
Mr. Craig A. Tooman M.B.A., MBAChief Financial OfficerN/DN/D1966
Ms. Gem Gokmen HopkinsHead of IR & Corp. CommunicationsN/DN/DN/D
Dr. Barbara A. RuskinSr. VP, Gen. Counsel & Chief Patent OfficerN/DN/D1960
Ms. Linnea ElringtonVP & Head of HRN/DN/DN/D
Dr. John Strafford Ph.D.Sr. VP of Bus. Devel., Alliance Management & New Product Devel.N/DN/DN/D
Mr. Jørgen WittendorffSr. VP & Head of ManufacturingN/DN/DN/D
Dr. Marie Wikstrom Lindholm Ph.D.Sr. VP & Head of Molecular DesignN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Silence Therapeutics plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.